TrialCancer science2025

Durvalumab Post Concurrent Chemoradiotherapy in Japanese Patients With Limited-Stage Small-Cell Lung Cancer in the Phase 3 ADRIATIC Trial.

Yoshitaka Zenke et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.